Gender-Related Differences in Outcome for Melanoma Patients
Top Cited Papers
- 1 May 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 243 (5) , 693-700
- https://doi.org/10.1097/01.sla.0000216771.81362.6b
Abstract
To better understand the factors associated with the well-established gender difference in survival for patients with melanoma. Gender is an important factor in patients with cutaneous melanoma. Male patients have a worse outcome when compared with females. The reasons for this difference are poorly understood. This prospective multi-institutional study included patients aged 18 to 70 years with melanomas > or =1.0 mm Breslow thickness. Wide excision and sentinel lymph node (SLN) biopsy was performed in all patients. Clinicopathologic factors, including gender, were assessed and correlated with disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS). A total of 3324 patients were included in the covariate analyses; 1829 patients had follow-up data available and were included in the survival analyses. Median follow-up was 30 months. On univariate analysis, men (n = 1906) were more likely than women to be older than 60 years (P < 0.0001), have thicker melanomas (P < 0.0001), have primary tumor regression (P = 0.0054), ulceration (P < 0.0001), and axial primary tumor location (P < 0.0001). On multivariate analysis, age (P = 0.0002), thickness (P < 0.0001), ulceration (P = 0.015), and location (P < 0.0001) remained significant in the model. There was no difference in the rate of SLN metastasis between men and women (P = 0.37) on multivariate analysis. When factors affecting survival were considered, the prognosis was worse for men as validated by lower DFS (P = 0.0005), DDFS (P < 0.0001), and OS (P < 0.0001). Male gender is associated with a greater incidence of unfavorable primary tumor characteristics without an increased risk for nodal metastasis. Nonetheless, gender is an independent factor affecting survival.Keywords
This publication has 42 references indexed in Scilit:
- Predictors of Nonsentinel Lymph Node Positivity in Patients with a Positive Sentinel Node for MelanomaJournal of the American College of Surgeons, 2005
- Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for MelanomaJournal of Clinical Oncology, 2004
- Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous MelanomaAnnals of Surgical Oncology, 2004
- Lessons learned from the Sunbelt Melanoma TrialJournal of Surgical Oncology, 2004
- Use of tamoxifen in the treatment of malignant melanomaCancer, 2003
- Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed?Annals of Surgical Oncology, 2001
- Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patientsMelanoma Research, 2001
- Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (?4 mm) Primary MelanomaAnnals of Surgical Oncology, 2000
- Cutaneous melanoma: Prognosis and treatment results worldwideSeminars in Surgical Oncology, 1992
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989